KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Income from Continuing Operations for 7 consecutive years, with 210835000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 14174.54% year-over-year to 210835000.0, compared with a TTM value of 287202000.0 through Dec 2025, up 4893.08%, and an annual FY2025 reading of 287202000.0, up 4893.08% over the prior year.
  • Income from Continuing Operations was 210835000.0 for Q4 2025 at Aurinia Pharmaceuticals, up from 31462000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 210835000.0 in Q4 2025 and bottomed at 50379000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 3709500.0, with a median of 12472500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 93.99% in 2021, then soared 14174.54% in 2025.
  • Year by year, Income from Continuing Operations stood at 33322000.0 in 2021, then grew by 21.92% to 26018000.0 in 2022, then dropped by 3.29% to 26875000.0 in 2023, then surged by 105.5% to 1477000.0 in 2024, then skyrocketed by 14174.54% to 210835000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AUPH at 210835000.0 in Q4 2025, 31462000.0 in Q3 2025, and 21556000.0 in Q2 2025.